NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
Portfolio Pulse from
Novo Nordisk's stock fell by 9% after its obesity drug candidate, CagriSema, achieved only a 15.7% weight loss in a phase III study, missing the 25% target.
March 11, 2025 | 7:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's stock dropped 9% due to CagriSema's failure to meet the expected 25% weight loss target in a phase III study, achieving only 15.7%.
The stock price of Novo Nordisk (NVO) is negatively impacted due to the underperformance of its obesity drug candidate, CagriSema, in a critical phase III study. The market likely reacted to the news as the drug did not meet the anticipated weight loss target, which is crucial for its success and potential market adoption.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100